Phase 1 trial tests re-radiation plus immunotherapy and a cancer pill
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent (coming back) head and neck cancer needing radiation to a nearby area
- Your oropharynx (throat) tumor is HPV-positive, confirmed by p16 testing
- You have available tumor material: at least 10 unstained slide samples, or you can get a new biopsy
- Your cancer has either no distant spread, or only limited spread that can be treated with focused radiation or other curative treatment
- You’re an adult (18+) and can handle treatment: life expectancy over 12 weeks, and good overall strength for daily activities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.